These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia. Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560 [TBL] [Abstract][Full Text] [Related]
3. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Sera T; Hiasa Y; Michitaka K; Konishi I; Matsuura K; Tokumoto Y; Matsuura B; Kajiwara T; Masumoto T; Horiike N; Onji M Intern Med; 2006; 45(11):721-4. PubMed ID: 16819252 [TBL] [Abstract][Full Text] [Related]
4. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia. Le Garff-Tavernier M; Herbi L; de Romeuf C; Azar N; Roos-Weil D; Bonnemye P; Urbain R; Leblond V; Merle-Beral H; Vieillard V Haematologica; 2015 Apr; 100(4):e147-51. PubMed ID: 25552707 [No Abstract] [Full Text] [Related]
5. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia. Basse G; Ribes D; Kamar N; Esposito L; Rostaing L Clin Nephrol; 2006 Nov; 66(5):395-6. PubMed ID: 17140171 [No Abstract] [Full Text] [Related]
6. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Terrier B; Ittah M; Tourneur L; Louache F; Soumelis V; Lavie F; Casadevall N; Candon S; Hummel A; Mariette X; Buzyn A Haematologica; 2007 Feb; 92(2):e20-3. PubMed ID: 17405749 [TBL] [Abstract][Full Text] [Related]
7. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia]. Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772 [TBL] [Abstract][Full Text] [Related]
8. Fulminant hepatitis due to human adenovirus. Ronan BA; Agrwal N; Carey EJ; De Petris G; Kusne S; Seville MT; Blair JE; Vikram HR Infection; 2014 Feb; 42(1):105-11. PubMed ID: 23979854 [TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. Gironi M; Saresella M; Ceresa L; Calvo M; Ferrante P; Merli F; Nemni R Haematologica; 2006 Jun; 91(6 Suppl):ECR17. PubMed ID: 16785123 [No Abstract] [Full Text] [Related]
10. Development of nasal skin necrosis associated with rituximab treatment for Waldenström's macroglobulinemia and subsequent spontaneous resolution. Pearlman AN; Fechner FP; Constantinides M Ear Nose Throat J; 2006 Jul; 85(7):431-3. PubMed ID: 16909812 [TBL] [Abstract][Full Text] [Related]
11. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia. Mauermann ML; Ryan ML; Moon JS; Klein CJ J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458 [TBL] [Abstract][Full Text] [Related]
12. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Chew E; Thursky K; Seymour JF Leuk Lymphoma; 2014 Apr; 55(4):938-9. PubMed ID: 23772645 [No Abstract] [Full Text] [Related]
13. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Massari M; Catania A; Magnani G Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216 [No Abstract] [Full Text] [Related]
14. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. Schadlow MB; Anhalt GJ; Sinha AA J Drugs Dermatol; 2003 Oct; 2(5):564-7. PubMed ID: 14558407 [TBL] [Abstract][Full Text] [Related]
15. Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia. Meersseman W; Lagrou K; Sciot R; de Jonckheere J; Haberler C; Walochnik J; Peetermans WE; van Wijngaerden E Emerg Infect Dis; 2007 Mar; 13(3):469-71. PubMed ID: 17552103 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of severe refractory pemphigus vulgaris with rituximab]. Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052 [TBL] [Abstract][Full Text] [Related]
18. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Weide R; Heymanns J; Köppler H Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038 [TBL] [Abstract][Full Text] [Related]
19. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407 [TBL] [Abstract][Full Text] [Related]